|
[1]
|
Powers AC, Aronoff DM, Eckel RH. COVID-19 vaccine prioritisation for type 1 and type 2 diabetes. Lancet Diabetes Endocrinol 2021;9(3):140 − 1. http://dx.doi.org/10.1016/S2213-8587(21)00017-6CrossRef
|
|
[2]
|
CDC. Evidence to recommendation framework: Pfizer-BioNTech COVID-19 Booster Dose. 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/11-COVID-Dooling-508.pdf. [2021-10-20].https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/11-COVID-Dooling-508.pdf |
|
[3]
|
Duan LR, Wang Y, Dong HY, Song CY, Zheng JP, Li J, et al. The COVID-19 vaccination behavior and correlates in diabetic patients: a health belief model theory-based cross-sectional study in China, 2021. Vaccines 2022;10(5):659. http://dx.doi.org/10.3390/vaccines10050659CrossRef
|
|
[4]
|
Scoccimarro D, Panichi L, Ragghianti B, Silverii A, Mannucci E, Monami M. Sars-CoV2 vaccine hesitancy in Italy: a survey on subjects with diabetes. Nutr Metabol Cardiovasc Dis 2021;31(11):3243 − 6. http://dx.doi.org/10.1016/j.numecd.2021.09.002CrossRef
|
|
[5]
|
Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8(6):546 − 50. http://dx.doi.org/10.1016/S2213-8587(20)30152-2CrossRef
|
|
[6]
|
Wong LP, Alias H, Danaee M, Ahmed J, Lachyan A, Cai CZ, et al. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. Infect Dis Poverty 2021;10(1):122. http://dx.doi.org/10.1186/s40249-021-00900-wCrossRef
|
|
[7]
|
Kaplan RM, Milstein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci USA 2021;118(10):e2021726118. http://dx.doi.org/10.1073/pnas.2021726118CrossRef
|
|
[8]
|
Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang BB, et al. Factors associated with US Adults’ likelihood of accepting COVID-19 vaccination. JAMA Netw Open 2020;3(10):e2025594. http://dx.doi.org/10.1001/jamanetworkopen.2020.25594CrossRef
|
|
[9]
|
Wang CH, Jones J, Hilliard ME, Tully C, Monaghan M, Marks BE, et al. Correlates and patterns of COVID-19 vaccination intentions among parents of children with type 1 diabetes. J Pediatr Psychol 2022;47(8):883 − 91. http://dx.doi.org/10.1093/jpepsy/jsac048CrossRef
|
|
[10]
|
Ai JW, Zhang HC, Zhang QR, Zhang Y, Lin K, Fu ZF, et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern. Cell Res 2022;32(1):103 − 6. http://dx.doi.org/10.1038/s41422-021-00590-xCrossRef
|
|
[11]
|
Zhang YT, Chen HP, Lv J, Huang T, Zhang RZ, Zhang DJ, et al. Evaluation of immunogenicity and safety of Vero cell-derived inactivated COVID-19 vaccine in older patients with hypertension and diabetes mellitus. Vaccines 2022;10(7):1020. http://dx.doi.org/10.3390/vaccines10071020CrossRef
|
|
[12]
|
Wan EYF, Mok AHY, Yan VKC, Wang BY, Zhang R, Hong SN, et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: a case control study. J Infect 2022;85(5):e140 − 4. http://dx.doi.org/10.1016/j.jinf.2022.08.008CrossRef
|